Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/40514
Title: Deflazacort: A glucocorticoid with few metabolic adverse effects but important immunosuppressive activity
Author: Velarde-Felix, J.S.
Salazar-Flores, J.
Martinez-Cortes, G.
Flores García, A.
Munoz-Valle, J.F.
Rios-Tostado, J.J.
Rubi-Castellanos, R.
Rangel-Villalobos, H.
Issue Date: 2011
Abstract: The amelogenin represents the gender marker most widely used for human identification and biomedical purposes. However, some failures in sex-typing have been observed globally. In this study, we could approximate the population frequency of AMELY negative males in 1230 individuals from five states of Mexico (0.081%). For the sole AMELY negative male detected, we constructed a deletion map by means of 10 markers (7 STS and 3 Y-STRs). This allowed classifying the case into the most common category (Class I deletion), according to the nomenclature proposed by Jobling et al. (2007). Interestingly, the Mexican sample was R1a1 *, a Y-chromosome haplogroup non-previously reported for AMELY negative cases. The geographic distribution of R1a1 *, and the Y-STR haplotype similarity with a reported case from Slovenia, suggests an Eastern-Europe paternal origin for this case from Mexico. To our knowledge, this is the first report in Latin America that implies a low population frequency and European paternal origin of AMELY negative cases. " 2011 Elsevier Ireland Ltd.",,,,,,"10.1016/j.legalmed.2011.06.001",,,"http://hdl.handle.net/20.500.12104/40514","http://www.scopus.com/inward/record.url?eid=2-s2.0-80052151540&partnerID=40&md5=be4595fced3315ad49364d49016d622e",,,,,,"5",,"Legal Medicine",,"262
264",,"13",,"Scopus
WOS",,,,,,"AMELY deletions; AMELY negative; Gender-typing; Mexican population; Sex-typing",,,,,,"Deletion mapping and paternal origin of a Mexican AMELY negative male",,"Article" "42298","123456789/35008",,"Gutiérrez-Plascencia, P., Servicio de Neurología, Hospital Civil de Guadalajara, Fray Antonio Alcalde, Hospital 278. CP 44280, Guadalajara, Jalisco, Mexico; Carmen Ruiz-Sandoval, M., Servicio de Neuropsicología., Hospital Civil de Guadalajara, Fray Antonio Alcalde, Mexico; Martínez-Rocha, M., Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico; Chiquete, E., Servicio de Medicina Interna, Hospital Civil de Guadalajara, Fray Antonio Alcalde, Mexico; Zúñiga-Ramírez, C., Servicio de Neurología, Hospital Civil de Guadalajara, Fray Antonio Alcalde, Hospital 278. CP 44280, Guadalajara, Jalisco, Mexico; Ruiz-Sandoval, J.L., Servicio de Neurología, Hospital Civil de Guadalajara, Fray Antonio Alcalde, Hospital 278. CP 44280, Guadalajara, Jalisco, Mexico, Departamento de Neurociencias., Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",,"Gutierrez-Plascencia, P.
Carmen Ruiz-Sandoval, M.
Martinez-Rocha, M.
Chiquete, E.
Zuniga-Ramirez, C.
Ruiz-Sandoval, J.L.",,"2012",,"[No abstract available]",,,,,,,,,"http://hdl.handle.net/20.500.12104/40519","http://www.scopus.com/inward/record.url?eid=2-s2.0-84857167451&partnerID=40&md5=72a3ea33bac25929bd34ae0bcbeb0d94",,,,,,"4",,"Revista de Neurologia",,"251
252",,"54",,"Scopus
WOS",,,,,,,,,,,,"Dementia associated with paradichlorobenzene poisoning [Demencia asociada a intoxicación por paradiclorobenceno]",,"Letter" "42282","123456789/35008",,"Gonzalez-Perez, O., Department of Neuroscience, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara, Mexico, Laboratory of Neuroscience, University of Colima School of Psychology, Colima, Mexico, Laboratory of Neuroscience, University of Colima School of Psychology, Av. Universidad #333, Colima, Colima 28040, Mexico; Luquin, S., Department of Neuroscience, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara, Mexico; García-Estrada, J., Department of Neuroscience, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Guadalajara, Mexico; Ramos-Remus, C., Department of Rheumatology, Centro Medico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico",,"Gonzalez-Perez, O.
Luquin, S.
García-Estrada, J.
Ramos-Remus, C.",,"2007",,"Deflazacort (DFZ) is a synthetic glucocorticoid that has few adverse effects on glucose and calcium metabolism and fewer deleterious effects on the neuronal population. Therefore, it may have a crucial role in the treatment of patients with autoimmune disorders associated with central nervous system or metabolic affectations. To date, the pharmacologic safety profile of DFZ is considered similar to that of other glucocorticoids. Nevertheless, cumulative clinical and laboratory evidence suggests that DFZ has, in fact, greater immunosuppressive activity than was previously thought. Therefore, it is possible that DFZ increases the risk of acquiring opportunistic infection compared with other synthetic glucocorticoids. Additional pharmacologic studies are needed to fully establish the immunosuppressive potency of DFZ and, consequently, to determine the appropriate ratio of bioequivalence in humans. "2007 Health Communications Inc.
URI: http://hdl.handle.net/20.500.12104/40503
http://www.scopus.com/inward/record.url?eid=2-s2.0-37249083012&partnerID=40&md5=8b5ea2fbc275f4cc7a2f473b3095c564
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.